Showing results (1041-1050 of 1,163) with videos related to

Sort By:
Pageof 117
European Heart Journal|November 20, 2024
Sodium-glucose co-transporter 2 inhibitors and new-onset diabetes in cardiovascular or kidney diseaseJohn W Ostrominski, Mats C Højbjerg Lassen, Brian L Claggett, et al.
European Journal of Heart Failure|March 15, 2024
Dapagliflozin in patients with heart failure and previous myocardial infarction: A participant-level pooled analysis of DAPA-HF and DELIVERAlexander Peikert, Muthiah Vaduganathan, Brian L Claggett, et al.
Lancet (London, England)|June 5, 2026
Efficacy and safety of finerenone in patients with chronic kidney disease: an individual participant data pooled analysis (INFINITY)Brendon L Neuen, Hiddo J L Heerspink, Vlado Perkovic, et al.
Journal of the American College of Cardiology|August 30, 2022
Atrial Fibrillation and Dapagliflozin Efficacy in Patients With Preserved or Mildly Reduced Ejection FractionJawad H Butt, Toru Kondo, Pardeep S Jhund, et al.
Journal of the American College of Cardiology|September 2, 2025
Anthropometric Measures, Cardiovascular Outcomes, and Treatment Effects of Finerenone in Cardiovascular-Kidney-Metabolic Disease: Pooled Participant-Level Analysis of Three Global TrialsJohn W Ostrominski, Josephine Harrington, Brian L Claggett, et al.
European Journal of Heart Failure|January 11, 2020
Genetic risk and atrial fibrillation in patients with heart failureMariëlle Kloosterman, Bernadet T Santema, Carolina Roselli, et al.
JAMA Cardiology|June 18, 2025
Finerenone According to Frailty in Heart Failure: A Prespecified Analysis of the FINEARTS-HF Randomized Clinical TrialJawad H Butt, Pardeep S Jhund, Alasdair D Henderson, et al.
European Journal of Heart Failure|November 4, 2025
Finerenone in patients with severe heart failure: The FINEARTS-HF trialRiccardo M Inciardi, Henri Lu, Brian L Claggett, et al.
Pageof 117